Wu H M, Lee A G, Lehane D E, Chi T L, Lewis R A
Department of Ophthalmology, Baylor College of Medicine, Houston, Texas 77030, USA.
J Neuroophthalmol. 1997 Sep;17(3):195-8.
Despite advances in neurosurgery, radiation oncology, and chemotherapy, the prognosis for glioblastoma multiforme remains poor, with a median survival time of 11-12 months. Cisplatin (cis-diamminedichlorideplatinum II) is one treatment for glioblastoma multiforme. Higher response rates have been achieved by intraarterial (i.a.) infusion than by systemic infusion of this agent. Cisplatin therapy may cause neurologic complications, and i.a. delivery has been reported to cause ocular toxicity. We report a patient who experienced intraorbital and intraocular toxicity following supraophthalmic i.a. injection of cisplatin.
尽管神经外科、放射肿瘤学和化疗取得了进展，但多形性胶质母细胞瘤的预后仍然很差，中位生存时间为11至12个月。顺铂（顺二氨二氯铂II）是多形性胶质母细胞瘤的一种治疗方法。动脉内（i.a.）输注该药物比全身输注能获得更高的缓解率。顺铂治疗可能会引起神经并发症，据报道动脉内给药会导致眼部毒性。我们报告了一名患者，在经眼上动脉内注射顺铂后出现眶内和眼内毒性。
